Last reviewed · How we verify
botulinum toxin neuromodulator
Botulinum toxin blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum toxin blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Chronic migraine, Cervical dystonia, Blepharospasm.
At a glance
| Generic name | botulinum toxin neuromodulator |
|---|---|
| Also known as | QM1114-DP |
| Sponsor | Galderma R&D |
| Drug class | Neuromuscular blocking agent |
| Target | SNARE complex (synaptobrevin, SNAP-25, syntaxin) |
| Modality | Biologic |
| Therapeutic area | Neurology, Aesthetics, Pain Management |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin is a neurotoxin that irreversibly cleaves proteins required for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission, resulting in temporary flaccid paralysis of targeted muscles. The effect is reversible over months as the body regenerates new neuromuscular junctions.
Approved indications
- Chronic migraine
- Cervical dystonia
- Blepharospasm
- Hyperhidrosis
- Spasticity
- Facial wrinkles and dynamic expression lines
Common side effects
- Headache
- Neck pain
- Injection site pain or bruising
- Muscle weakness
- Eyelid ptosis
- Antibody formation (neutralizing antibodies)
Key clinical trials
- Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture (PHASE1)
- Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area (NA)
- Botox Versus Tacrolimus in Psoriasis Vulgaris (PHASE4)
- Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides (EARLY_PHASE1)
- Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (PHASE3)
- Treatment of Moderate to Severe Glabellar Lines (PHASE3)
- Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (PHASE3)
- Treatment of Moderate to Severe Lateral Canthal Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- botulinum toxin neuromodulator CI brief — competitive landscape report
- botulinum toxin neuromodulator updates RSS · CI watch RSS
- Galderma R&D portfolio CI